An observational study in Migraine Disorders, sponsored by Allergan. Completed. Per ClinicalTrials.gov, last updated 2015-01-29.
Sponsored by Allergan · Observational
This is a population internet-based study to characterize migraine clinical course and impact on family.
1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.
This study's enrollment of 16,789 is above the median of 130 across 299 observational studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants with migraine
Exclusion Criteria:
Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
Other: No Treatment
No Treatment
Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM)
EM is defined as \<15 headache days/month and CM is defined as ≥15 headache days/month.
Time frame: Baseline
Migraine Disability Assessment (MIDAS)
The Midas score is a patient completed 5-item questionnaire about lost time and productivity (for work, school or family/social activities) in the past 3 months (number of days missed) where: 0-5=Little or No disability, 6-10=Mild disability, 11-20=Moderate disability or 21+ Severe disability. The Midas scores assessed at Months 3, 6, 9 and 12 were averaged.
Time frame: 12 Months
| Milestone | Participants With Migraines |
|---|---|
| Started | 16789 |
| Completed | 5915 |
| Not completed | 10874 |
EM is defined as \<15 headache days/month and CM is defined as ≥15 headache days/month.
| percentage of participants | Participants With Migraines |
|---|---|
| Episodic Migraine | 91.2 |
| Chronic Migraine | 8.8 |
The Midas score is a patient completed 5-item questionnaire about lost time and productivity (for work, school or family/social activities) in the past 3 months (number of days missed) where: 0-5=Little or No disability, 6-10=Mild disability, 11-20=Moderate disability or 21+ Severe disability. The Midas scores assessed at Months 3, 6, 9 and 12 were averaged.
| days | Participants With Episodic Migraine | Participants With Chronic Migraine |
|---|---|---|
| Migraine Disability Assessment (MIDAS) | 13.1 ± 22.2 | 60.5 ± 70.4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants With Migraines | — | — | — |
| Age, Continuous(years) | Participants With Migraines |
|---|---|
| Mean | 40.7 ± 14.4 |
| Sex: Female, Male(Participants) | Participants With Migraines |
|---|---|
| Female | 12495 |
| Male | 4294 |
No study locations are listed for this record.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergan